Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community

MerckMerck (NYSE:MRK), known as MSD outside the United States and Canada, has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines.

Biosimilars are a type of biological product that are approved by the U.S. Food and Drug Administration (FDA) because they are highly similar to an already FDA-approved biological product, known as the originator biologic or reference product, and have been shown to have no clinically meaningful differences in terms of the safety, purity and potency of the product.

"Biosimilars can offer alternative treatment options, and have the potential to help reduce healthcare spending and increase access to important biologic medicines," said Dora Bibila, general manager, Merck Biosimilars. "At Merck, we want to provide educational resources for patients and caregivers to help them get the information they want and need. We believe the more patients know, the more they can be in charge of their health - Biosimilars Clarified is designed to help answer their questions about biosimilars."

Biosimilars Clarified offers a host of informative features in a simple, easy-to-use question-and-answer format. The website was developed to provide patients, their caregivers, healthcare professionals and others clarification on such topics as:

  • What are biologic medicines?
  • Biosimilars - are they safe and effective?
  • The value of biosimilars and increasing access to treatment.
  • The availability of support programs for patients taking biosimilars.

"Merck is one of the largest pharmaceutical companies in the world today, and we have a long-standing commitment to supporting patients and the healthcare community. We are continuing that commitment with Merck Biosimilars," Bibila said.

For further information, please visit:
http://www.merckclarifiesbiosimilars.com

About Merck
For 125 years, Merck has been a global health care leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...